Histone deacetylase-6 modulates amyloid beta-induced cognitive dysfunction rats by regulating PTK2B

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Amyloid beta (Aβ) accumulation is linked to cognitive dysfunction and neurodegenerative diseases.
• Histone deacetylase-6 (HDAC6) plays a role in cellular processes relevant to neuronal function.
• Protein tyrosine kinase 2 beta (PTK2B) is implicated in signaling pathways affecting neuronal plasticity and survival.

Purpose of the Study:

• To investigate the role of HDAC6 in Aβ-induced cognitive dysfunction in rats.
• To explore the regulatory effect of HDAC6 on PTK2B in this model.
• To evaluate the therapeutic potential of targeting HDAC6 and PTK2B.

Main Methods:

• Ninety Sprague Dawley rats were used, divided into experimental and control groups.
• Intracerebroventricular infusion of Aβ1-42 was used to induce cognitive dysfunction.
• Rats received treatments including an HDAC6 inhibitor (tubastatin A hydrochloride), an HDAC agonist (theophylline), a PTK2B inhibitor (PF431396), or combinations thereof.

Main Results:

• HDAC6 upregulation was associated with impaired learning and memory in Aβ-treated rats.
• HDAC6 inhibition ameliorated cognitive deficits and reduced Aβ oligomers (Aβo) and Tau phosphorylation.
• Upregulation of PTK2B by HDAC6 was identified as a key mechanism in the observed pathology.

Conclusions:

• HDAC6 contributes to cognitive deterioration and neuropathological changes in Aβ-induced dysfunction.
• Targeting HDAC6 may offer a therapeutic strategy for conditions involving amyloid pathology.
• PTK2B is a crucial mediator in the detrimental effects of HDAC6 on cognitive function.